Outcome comparison between radiation therapy and surgery as primary treatment for dogs with periarticular histiocytic sarcoma: An Italian Society of Veterinary Oncology study.
amputation
canine
histiocytic disorder
joint
radiotherapy
Journal
Veterinary and comparative oncology
ISSN: 1476-5829
Titre abrégé: Vet Comp Oncol
Pays: England
ID NLM: 101185242
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
28
01
2020
revised:
30
04
2020
accepted:
07
05
2020
pubmed:
13
5
2020
medline:
9
9
2021
entrez:
13
5
2020
Statut:
ppublish
Résumé
Localized histiocytic sarcoma may occur as a primary lesion in periarticular tissues of large appendicular joints. Treatment options for the primary lesion include radical surgical excision, radiation therapy (RT), or both, in combination with chemotherapy for potential systemic metastases. In an effort to better characterize the time to progression (TTP) following surgical vs non-surgical approaches for periarticular histiocytic sarcoma (PAHS), a contemporary European population of affected dogs was retrospectively surveyed. Medical records were queried for newly-diagnosed PAHS cases undergoing surgery (predominantly limb amputation) or RT followed by systemic chemotherapy. Of 49 dogs, 34 underwent RT and 15 underwent surgery. All dogs received adjuvant chemotherapy. There was no statistically significant difference in TTP or overall survival between groups. The median TTP was 336 days for the operated dogs and 217 days for the irradiated dogs (P = .117). The median overall survival time was 398 days for the operated dogs and 240 days for the irradiated dogs (P = .142). On multi-variable analysis, the variables significantly associated with an increased risk of both tumour progression and tumour-related death were regional lymph node and distant metastasis at admission. Survival and local control rates following RT may be comparable to radical resection. These data may better inform shared decision-making processes between multi-disciplinary care providers and owners.
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
778-786Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Fidel J, Schiller I, Hauser B, et al. Histiocytic sarcomas in flat-coated retrievers: a summary of 37 cases (November 1998-March 2005). Vet Comp Oncol. 2006;4:63-74.
Craig LE, Julian ME, Ferracone JD. The diagnosis and prognosis of synovial tumors in dogs: 35 cases. Vet Pathol. 2002;39:66-73.
van Kuijk L, van Ginkel K, de Vos JP, et al. Peri-articular histiocytic sarcoma and previous joint disease in Bernese Mountain dogs. J Vet Intern Med. 2013;27:293-299.
Harasen GL, Simko E. Histiocytic sarcoma of the stifle in a dog with cranial cruciate ligament failure and TPLO treatment. Vet Comp Orthop Traumatol. 2008;21:375-377.
Cannon C, Borgatti A, Henson M, Husbands B. Evaluation of a combination chemotherapy protocol including lomustine and doxorubicin in canine histiocytic sarcoma. J Small Anim Pract. 2015;56:425-429.
Manor EK, Craig LE, Sun X, Cannon CM. Prior joint disease is associated with increased risk of periarticular histiocytic sarcoma in dogs. Vet Comp Oncol. 2018;16:E83-E88.
Schultz RM, Puchalski SM, Kent M, Moore PF. Skeletal lesions of histiocytic sarcoma in nineteen dogs. Vet Radiol Ultrasound. 2007;48:539-543.
Klahn SL, Kitchell BE, Dervisis NG. Evaluation and comparison of outcomes in dogs with periarticular and nonperiarticular histiocytic sarcoma. J Am Vet Med Assoc. 2011;239(1):90-96.
Veterinary Co-operative Oncology Group. Veterinary co-operative oncology group-common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy for biological antineoplastic therapy in dogs and cats. Vet Comp Oncol. 2004;2:195-231.
Nguyen SM, Thamm DH, Vail DM, London CA. Response evaluation criteria for solid tumours in dogs (v1.0): a veterinary cooperative oncology group (VCOG) consensus document. Vet Comp Oncol. 2015;13:176-183.
International Commission on Radiation Units and Measurements. Prescribing, Recording, and Reporting Photon Beam Therapy (Report 50). Bethesda, MD; 1993.
International Commission on Radiation Units and Measurements. Prescribing, Recording, and Reporting Photon Beam Therapy (Report 62, Supplement to ICRU Report 50). Bethesda, MD; 1999.
International Commission on Radiation Units and Measurements. Prescribing, Recording, and Reporting Photon-Beam Intensity-Modulated Radiation Therapy (IMRT) (Report 83). Oxford: Oxford University Press; 2010.
Rohrer Bley C, Meier VS, Besserer J, Schneider U. Intensity-modulated radiation therapy dose prescription and reporting: sum and substance of the international commission on radiation units and measurements report 83 for veterinary medicine. Vet Radiol Ultrasound. 2019;60:255-264.
Keyerleber MA, McEntee MC, Farrelly J, Podgorsak M. Completeness of reporting of radiation therapy planning, dose, and delivery in veterinary radiation oncology manuscripts from 2005 to 2010. Vet Radiol Ultrasound. 2012;53:221-230.
Athanasiadi I, Geigy C, Hilger RA, Meier V, Rohrer BC. Safety, tolerability and pharmacokinetic properties of the novel triazene TriN 2755 in tumour bearing dogs - a phase I study(dagger). Vet Comp Oncol. 2017;15:94-104.
Affolter VK, Moore PF. Localized and disseminated histiocytic sarcoma of dendritic cell origin in dogs. Vet Pathol. 2002;39(1):74-83.